Gamma Biosciences, A Life Sciences Platform Established By KKR, Announces Sale Of Mirus Bio To Merck KGaA, Darmstadt, Germany, For $600M
Gamma Biosciences, A Life Sciences Platform Established By KKR, Announces Sale Of Mirus Bio To Merck KGaA, Darmstadt, Germany, For $600M
由KKR建立的生命科學平台Gamma Biosciences宣佈以6億美元的價格向德國達姆施塔特的默沙東KGaA出售Mirus Bio
Gamma Biosciences, a life sciences platform established by KKR to address the advanced therapy bioprocessing market, today announced that it has entered into an agreement with Merck KGaA, Darmstadt, Germany (XTRA:MRK), a leading science and technology company, whereby Merck KGaA, Darmstadt, Germany, will acquire Gamma operating company Mirus Bio for $600 million in cash.
今天，KKR成立的生命科學平台Gamma Biosciences宣佈已與領先的科學與科技公司默沙東（Merck KGaA，位於德國達姆斯塔特的科技企業，XTRA: MRK）達成協議，後者將以6億美元現金收購Gamma旗下的Mirus Bio公司。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。